Faculty Profiles - MORIHARA Ryuuta

Papers - MORIHARA Ryuuta

Division display 21 - 40 of about 134 ／ All the affair displays >>

脊髄性筋萎縮症患者7名に対するリスジプラムの治療効果 Reviewed

山下徹, 柚木太淳, 中田有美, 松岡千加, 佐々木涼, 田所功, 中野由美子, 武本麻美, 森原隆太, 石浦浩之

臨床神経学 63 ( Suppl. ) S215 - S215 2023.9

MRgFUS Vim ThalamotomyにおけるBrain Mapping Applicationの有効性 Reviewed

小坂田陽介, 平林秀裕, 森原隆太, 山下徹, 阿部康二, 久我純弘, 大西英之

臨床神経学 63 ( Suppl. ) S244 - S244 2023.9

Foix-Chavany-Marie症候群を呈した持続性部分てんかんの一例 Reviewed

佐々木諒, 柚木太淳, 中田有美, 松岡千加, 田所功, 中野由美子, 武本麻美, 森原隆太, 山下徹, 石浦浩之

臨床神経学 63 ( 9 ) 620 - 620 2023.9

エフガルチギモドへのスイッチを行った抗アセチルコリン受容体抗体・抗横紋筋抗体陽性の全身型重症筋無力症の一例 Reviewed

中野由美子, 佐々木諒, 中田有美, 松岡千加, 小坂田陽介, 田所功, 野村恵美, 柚木太淳, 武本麻美, 森原隆太, 山下徹, 石浦浩之

臨床神経学 63 ( 9 ) 621 - 621 2023.9

神経疾患患者における遠隔診療のニーズ調査 Reviewed

佐々木諒, 田所功, 福井裕介, 中野由美子, 柚木太淳, 武本麻美, 森原隆太, 山下徹

臨床神経学 63 ( Suppl. ) S261 - S261 2023.9

Foix-Chavany-Marie症候群を呈した持続性部分てんかんの一例 Reviewed

佐々木諒, 柚木太淳, 中田有美, 松岡千加, 田所功, 中野由美子, 武本麻美, 森原隆太, 山下徹, 石浦浩之

臨床神経学 63 ( 9 ) 620 - 620 2023.9

脊髄性筋萎縮症患者7名に対するリスジプラムの治療効果 Reviewed

山下徹, 柚木太淳, 中田有美, 松岡千加, 佐々木涼, 田所功, 中野由美子, 武本麻美, 森原隆太, 石浦浩之

臨床神経学 63 ( Suppl. ) S215 - S215 2023.9

エフガルチギモドへのスイッチを行った抗アセチルコリン受容体抗体・抗横紋筋抗体陽性の全身型重症筋無力症の一例 Reviewed

中野由美子, 佐々木諒, 中田有美, 松岡千加, 小坂田陽介, 田所功, 野村恵美, 柚木太淳, 武本麻美, 森原隆太, 山下徹, 石浦浩之

臨床神経学 63 ( 9 ) 621 - 621 2023.9

MRgFUS Vim ThalamotomyにおけるBrain Mapping Applicationの有効性 Reviewed

小坂田陽介, 平林秀裕, 森原隆太, 山下徹, 阿部康二, 久我純弘, 大西英之

臨床神経学 63 ( Suppl. ) S244 - S244 2023.9

抗AQP4抗体陽性のNMOsd患者の髄液におけるIL-6測定の有用性の検討 Reviewed

柚木太淳, 中田有美, 松岡千加, 田所功, 佐々木諒, 中野由美子, 武本麻実, 森原隆太, 山下徹, 石浦浩之

臨床神経学 63 ( Suppl. ) S298 - S298 2023.9

神経疾患患者における遠隔診療のニーズ調査 Reviewed

佐々木諒, 田所功, 福井裕介, 中野由美子, 柚木太淳, 武本麻美, 森原隆太, 山下徹

臨床神経学 63 ( Suppl. ) S261 - S261 2023.9

MRガイド下集束超音波療法による淡蒼球内節凝固術にて片側ジスキネジア改善を認めたパーキンソン病の一例

小坂田陽介, 平林秀裕, 久我純弘, 森原隆太, 山下徹, 阿部康二, 大西英之

臨床神経学 63 ( 6 ) 392 - 392 2023.6

ADSSL1遺伝子変異を認め心不全を発症したが早期介入にて改善しえたネマリンミオパチーの一例 Reviewed

柚木太淳, 中野由美子, 野村恵美, 中田有美, 佐々木諒, 田所功, 武本麻美, 森原隆太, 山下徹, 斎藤良彦, 西野一三

臨床神経学 63 ( 5 ) 322 - 322 2023.5

両側声帯麻痺から診断に至ったdouble seronegative myasthenia gravisの一例 Reviewed

中野由美子, 柚木太淳, 浦口健介, 中田有美, 佐々木諒, 田所功, 森原隆太, 山下徹

臨床神経学 63 ( 5 ) 322 - 322 2023.5

Neuroprotective effects of carnosine in a mice stroke model concerning oxidative stress and inflammatory response. Reviewed International journal

Xinran Hu, Yusuke Fukui, Tian Feng, Zhihong Bian, Haibo Yu, Ryuta Morihara, Xiao Hu, Yuting Bian, Hongming Sun, Mami Takemoto, Yumiko Nakano, Taijun Yunoki, Koji Abe, Toru Yamashita

Journal of the neurological sciences 447 120608 - 120608 2023.4

Language：English Publishing type：Research paper (scientific journal)

Carnosine (β-alanyl-L-histidine) is a natural dipeptide with multiple neuroprotective properties. Previous studies have advertised that carnosine scavenges free radicals and displays anti-inflammatory activity. However, the underlying mechanism and the efficacies of its pleiotropic effect on prevention remained obscure. In this study, we aimed to investigate the anti-oxidative, anti-inflammative, and anti-pyroptotic effects of carnosine in the transient middle cerebral artery occlusion (tMCAO) mouse model. After a daily pre-treatment of saline or carnosine (1000 mg / kg / day) for 14 days, mice (n = 24) were subjected to tMCAO for 60 min and continuously treated with saline or carnosine for additional 1 and 5 days after reperfusion. The administration of carnosine significantly decreased infarct volume 5 days after the tMCAO (*p < 0.05) and effectively suppressed the expression of 4-HNE, 8-OHdG, Nitrotyrosine 5 days, and RAGE 5 days after tMCAO. Moreover, the expression of IL-1β was also significantly suppressed 5 days after tMCAO. Our present findings demonstrated that carnosine effectively relieves oxidative stress caused by ischemic stroke and significantly attenuates neuroinflammatory responses related to IL-1β, suggesting that carnosine can be a promising therapeutic strategy for ischemic stroke.

DOI： 10.1016/j.jns.2023.120608

PubMed

researchmap

Actual Telemedicine Needs of Japanese Patients with Neurological Disorders in the COVID-19 Pandemic. Reviewed

Ryo Sasaki, Taijun Yunoki, Yumiko Nakano, Yusuke Fukui, Mami Takemoto, Ryuta Morihara, Koji Abe, Toru Yamashita

Internal medicine (Tokyo, Japan) 62 ( 3 ) 365 - 371 2023.2

Language：English Publishing type：Research paper (scientific journal)

Objective During the coronavirus disease 2019 (COVID-19) pandemic, many social activities have moved online using applications for digital devices (e.g. computers, smartphones). We investigated the needs of telemedicine and trends in medical status and social care situations of Japanese patients with neurological disorders in order to estimate their affinity for an online telemedicine application. Methods We designed an original questionnaire for the present study that asked participants what problems they had with hospital visits, how the COVID-19 pandemic had affected their lives, and whether or not they would like to receive telemedicine. Patients The present study included volunteer caregivers, participants with Parkinson's disease (PD), epilepsy, stroke, dementia, immune-mediated neurological disease (IMMD), spinocerebellar degeneration (SCD), amyotrophic lateral sclerosis (ALS), headache, myopathy, and other neurological diseases from Okayama University Hospital. Results A total of 29.6% of patients wanted to use telemedicine. Patients with headaches (60.0%) and epilepsy (38.1%) were more likely to want to use telemedicine than patients with PD (17.8%) or stroke (19.0%). Almost 90% of patients had access to a digital device, and there was no association between favoring telemedicine, ownership of a digital device, hospital visiting time, or waiting time at the hospital, although age was associated with motivation to telemedicine use (52.6 vs. 62.2 years old, p <0.001*). Conclusion We can contribute to the management of the COVID-19 pandemic and the medical economy by promoting telemedicine, especially for young patients with headaches or epilepsy.

DOI： 10.2169/internalmedicine.9702-22

PubMed

researchmap

A young female case of asymptomatic immune-mediated necrotizing myopathy: a potential diagnostic option of antibody testing for rhabdomyolysis. Reviewed International journal

Ryo Sasaki, Taijun Yunoki, Yumiko Nakano, Yusuke Fukui, Mami Takemoto, Ryuta Morihara, Eri Katsuyama, Ichizo Nishino, Toru Yamashita

Neuromuscular disorders : NMD 33 ( 2 ) 183 - 186 2023.2

Language：English

Anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) immune-mediated necrotizing myopathy (IMNM) is a neuromuscular disorder that presents muscle weakness in proximal extremities and/or the trunk with an elevation of creatine kinase (CK). Young and asymptomatic anti-HMGCR IMNM patients are very rare and a treatment regimen has not been established. The present case, a 17-year-old woman without any muscular symptoms, only showed hyperCKemia that was detected by chance. After close examinations, including a muscle biopsy and antibody search, she was diagnosed as anti-HMGCR IMNM, and initial treatment with methotrexate and continuous intravenous immunoglobulin seemed to be effective. The present case is the unusually young asymptomatic case of anti-HMGCR IMNM. The diagnosis was successfully made, leading to the early introduction of a treatment. Given the course of this case, we believe that the preceding antibody testing is one of the diagnostic option for rhabdomyolysis.

DOI： 10.1016/j.nmd.2022.12.012

PubMed

researchmap

脳低灌流アルツハイマー病マウスにおけるホタテ由来プラズマローゲンの脳血管保護効果 Reviewed

福井裕介, ZHAI Yun, FENG Tian, 森原隆太, 石浦浩之, 山下徹

日本脳サプリメント学会(Web) 5th 2023

エフガルチギモドへのスイッチを行った抗アセチルコリン受容体抗体・抗横紋筋抗体陽性の全身型重症筋無力症の一例

中野由美子, 佐々木諒, 中田有美, 松岡千加, 小坂田陽介, 田所功, 野村恵美, 柚木太淳, 武本麻美, 森原隆太, 山下徹, 石浦浩之

臨床神経学(Web) 63 ( 9 ) 2023

Exogenous amyloid-β oligomers exacerbate cognitive deficits and activated necroptosis in APP23 mice Reviewed

胡欣冉, 于海波, 山下徹, 森原隆太, 福井裕介, 石浦浩之

脳循環代謝(Web) 35 ( 1 ) 2023

　 PREV - NEXT 　

< MORIHARA Ryuuta >

Papers - MORIHARA Ryuuta